

December 2015: NEWSLETTER


TO OUR SHAREHOLDERS AND FRIENDS:

This is an exciting time for NeOnc TECHNOLOGIES INC. (NeOnc) as we get close to the launch of our Clinical Trial for NEO100. Agreements and protocols are being finalized with each of the six centers involved.

CLINICAL TRIAL

NeOnc is undertaking a Phase 1/2a clinical trial of NEO100 (highly purified perillyl alcohol) in patients with recurrent glioblastoma multiforme, one of the deadliest forms of brain cancer. The trial has received fast-track status with the FDA, which allows for more frequent meetings and more frequent written communication with the FDA, and can result in accelerated approval or priority review if the requisite criteria are met.

We are in the process of gaining approval to conduct the clinical trial at up to six centers including, the University of Southern California, the University of California San Francisco, the University of Wisconsin, the Cleveland Clinic, Dana Farber Cancer Institute, and the Seattle Cancer Care Alliance.



NeOnc recently held a pre-Clinical Trial meeting to discuss details and procedures. Dr. Thomas mfc00062995-mediumChen, CEO and Chairman of NeOnc, and Professor of Neurological Surgery at the University of Southern California presided over the meeting, which brought together NeOnc executives and researchers, representatives from all six trial sites, experts in this and related areas, and NeOnc partners Norac Pharmaceuticals, who is providing the NEO100 for the trial, and ClinDatix, who has been chosen as the Contract Research Organization for the trial.

The trial protocol is currently undergoing approval with the Institutional Review Board (IRB) of each center, and will get underway as each board's requirements are satisfied. The Cleveland Clinic is expected to start trials in January 2016 followed by the other sites throughout the year.

“With the start of the clinical trials for NEO100 POH, the preparation of the IND for NEO 212 TMZ-POH and continued research into other compounds, the future is bright.”

– Dr. Thomas Chen, Chairman and CEO

RESEARCH

NeOnc's lab stays very busy with several compounds being tested. In addition to the trial above, NEO100 may also be useful for treating brainstem gliomas and newly-diagnosed gliomas, which we will be looking into. Following NEO100, the next compound we will focus on is NEO212, which is produced by conjugating perillyl alcohol (POH) with temozolomide (TMZ), a chemotherapy drug used today. Plans call for this compound to be submitted for IND for use in both intracranial metastases and nasopharyngeal carcinoma, as well as glioblastoma. Future plans include testing of compounds that combine POH with rolipram, valproic acid, and 3-bromopyruvate to utilize the different mechanisms of action of each.

We're also working on POH and POH-TMZ, dissolved with a solvent to develop an intravenous use.

INTELLECTUAL PROPERTY

Here are the additions to the IP library since the last newsletter:

PATENTS

METHOD OF TREATING NASOPHARYNGEAL CARCINOMA USING PERILLYL ALCOHOL DERIVATIVE

- U.S. AND PCT APPLICATIONS – FILED

PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES

- U.S. (TWO PATENTS) AND CHINESE APPLICATIONS – ALLOWED AND ISSUED

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

- JAPAN AND CHINA APPLICATIONS – ALLOWED
- U.S. – ISSUED

METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL

- U.S. – ALLOW

TRADEMARKS

NeOnc TRADEMARK
ALLOWED U.S., KOREA, TAIWAN

FUNDING

Management closed the private placement memorandum in which many of you participated. The offering was over subscribed. Management is pursuing a licensing arrangement for NEO 212 TMZ-POH similar to the current agreement for NEO100 POH.